drugset / Trial / NCT01460251

OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277

NCT01460251 ↗

Phase 3 Terminated 11 enrolled Rabin Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The study is an open-label extension study, offering patients who participated and completed previous studies 901 and 910 (an extension to 901) to continue treatment with DiaPep277 and clinical follow-up, for up to 3 additional years.The aim of the study is to collect safety and efficacy data of long term treatment effect of Diapep277.Only patients who completed studies 901 or 910 and still have stimulated C-peptide level equal to or above 0.2 nmol/L will be eligible for this extension study

Timeline

Start
2012-01
Primary completion
2014-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DiaPep277 Peptide 1 mg —